Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Phase 2

Active, not recruiting

• Conditions: Parkinson's Disease
• Interventions: Drug: BIA 28-6156 10 mg; Drug: Placebo; Drug: BIA 28-6156 60 mg

• Registration Number: NCT05819359
• Lead Sponsor: Bial R&D Investments, S.A.

Brief Summary

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).

Detailed Description

This is a 2-part (Part A \[Genetic Screening\] and Part B \[Double-Blind Treatment\]), Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of 2 fixed dose levels of BIA 28-6156 (10 and 60 mg/day) in approximately 237 subjects with genetically confirmed GBA-PD.

Part A (Genetic Screening) will identify individuals with a PD risk-associated variant in the GBA1 gene for potential enrolment into Part B (Double-Blind Treatment) of the study. Part B will consist of a screening period to ensure that all protocol inclusion/exclusion criteria for Part B of the study are met (up to 5 weeks). After screening period, eligible subjects will be randomized into 1 of 3 treatment arms (BIA 28-6156 10 mg/day, BIA 28-6156 60 mg/day, or placebo) in a 1:1:1 ratio, and enter a double-blind treatment period up to 78 weeks, followed by a 30-day (4 weeks) of safety follow-up period.

Subjects must be receiving a stable dose of PD medication for at least 30 days before screening (for Part B \[Double-Blind Treatment\]) and will continue to receive their usual PD medications throughout the study.

Study Timeline

• Study Start: 2023-03-31
• Study First Submitted: 2023-04-06
• Study First Submitted QC: 2023-04-18
• Study First Posted: 2023-04-19
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-20
• Last Update Posted: 2024-08-21
• Primary Completion: 2026-03-31
• Study Completion: 2026-07-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 237

Inclusion Criteria

Subjects who satisfy all of the following criteria will be eligible for Part A (Genetic Screening) of the study:

• The subject is ≥35 and ≤80 years of age at the time of informed consent.
• The subject has a clinical diagnosis of PD for at least 1 year and for no longer than 7 years before initiation of screening (for Part A), as confirmed by a neurologist using the MDS Criteria for Parkinson's Disease.
• The subject has a modified Hoehn and Yahr score ≤2.5.
• The subject is receiving symptomatic treatment for PD.
• The subject is capable of giving signed informed consent.

Subjects who satisfy all the following criteria will be eligible for Part B (Double-Blind Treatment) of the study:

• Informed Consent - The subject is capable of giving signed informed consent.
• The subject has a known GBA-PD risk-associated variant (as determined in Part A [Genetic Screening] of this study).
• The subject has a score ≥22 on the Montreal Cognitive Assessment (MoCA) scale.
• The subject does not have severe motor fluctuations or disabling dyskinesias in the clinical judgment of the investigator.
• The subject has been on stable doses of PD medications for at least 30 days (at least 60 days for rasagiline) before initiation of screening in Part B (Double-Blind Treatment).
• The subject is able to comply with the study restrictions.
• The subject has a body mass index (BMI) of 18 to 40 kg/m2.
• If a sexually active man or a women of childbearing potential, the subject agrees to use highly effective birth control or to remain abstinent during the trial and for 30 days after the last dose of IMP. Complete abstinence from sexual intercourse if this is the subject's usual and preferred lifestyle; or sexual partner with surgical sterilization (e.g., tubal ligation, hysterectomy and/or bilateral oophorectomy, vasectomy).

Read More

Exclusion Criteria

• Individuals who do not satisfy the inclusion criteria for Part A (Genetic Screening) will be excluded.

Subjects who meet any of the following criteria for Part B (Double-Blind Treatment) are not eligible for the study.

• The subject has Gaucher's disease (GD), as defined by clinical signs and symptoms (i.e., hepatosplenomegaly, cytopenia, skeletal disease), and/or a medical history of marked deficiency of GCase activity compatible with GD.
• The subject is homozygous for a GBA1 pathogenic variant that is known to be associated with GD or compound heterozygous for 2 alleles that are known to be associated with GD.
• The subject carries a known PD-associated LRRK2 pathogenic variant.
• The subject has atypical or secondary parkinsonism by medical history or in the opinion of the investigator. Atypical parkinsonism includes, but is not limited to, diagnoses of progressive supranuclear palsy, cortico-basal syndrome, and multiple system atrophy. Secondary parkinsonism includes drug-induced, toxin-induced, postinfectious, posttraumatic, or vascular parkinsonism.
• The subject has a history of (within 60 days before initiation of screening) or has planned upcoming major surgery that could interfere with, or for which the treatment might interfere with, the conduct of the study or that would pose an unacceptable risk to the subject in the opinion of the investigator.
• The subject has any active or chronic disease or condition other than PD that could interfere with, or for which the treatment might interfere with, the conduct of the study or pose an unacceptable risk to the subject in the opinion of the investigator based on medical history, physical examination, vital signs, 12-lead ECG, or clinical laboratory tests. Minor deviations of laboratory values from the normal range may be acceptable if judged by the investigator to have no/minor clinical relevance.
• The subject has a recent history (last 6 months) of abuse of addictive substances (alcohol, illegal substances), currently uses >21 units of alcohol per week, or is a regular recreational user of sedatives, hypnotics, tranquillizers, or any other addictive agent in the opinion of the investigator.
• The subject has a positive test for drugs of abuse at screening or before administration of the first dose of investigational medicinal product (IMP) that the investigator judges as clinically relevant. A positive test for tetrahydrocannabinol (THC) is exclusionary. A positive test for cannabinoids (not containing THC) is not exclusionary if the subject is a recreational user (not an abuser) of cannabinoids, in the opinion of the investigator, and agrees to abstain from using cannabinoids within 12 hours before study visits. A positive drug screen that is attributed to an allowed prescription drug is not exclusionary but should be agreed with the medical monitor.
• The subject is currently pregnant, is planning pregnancy within the timeframe of the study, or is breastfeeding.
• The subject is using a strong inhibitors and inducers CYP3A4 at the time of screening for Part B (Double-Blind Treatment).
• The subject is using a breast cancer resistance protein (BCRP) substrate (e.g., pravastatin, rosuvastatin, glyburide) at the time of screening for Part B (Double-Blind Treatment).
• The subject has used any of the following medications within 60 days before Baseline: typical or atypical antipsychotics (including, but not limited to, clozapine, pimavanserin, olanzapine, risperidone, and aripiprazole), metoclopramide, prochlorperazine, methyldopa, tetrabenazine, deutetrabenazine, valbenazine, or reserpine.
• The subject has received a vaccination within 14 days before administration of the first dose of IMP.
• The subject has a prior history of or there is a plan to conduct deep brain stimulation (DBS), lesional procedures, (i.e., thalamotomy), or focused ultrasound; to initiate gene therapy treatment for PD; or to initiate use of any formulation of intestinal infusion or continuous subcutaneous infusion of PD medications.
• The subject is currently participating in or has participated in an investigational drug study within 3 months or 5 half-lives, whichever is longer; in a therapeutic device study within 3 months before the first dose of IMP; or has previously participated in a gene therapy trial. Concurrent participation in an observational study is acceptable.
• The subject has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), or human immunodeficiency virus 1 (HIV-1) or 2 (HIV-2) at screening. If reflex testing for hepatitis B or HCV DNA is negative, the subject may be eligible for the study.
• The subject has renal insufficiency as defined by an estimated glomerular filtration rate (eGFR) of <60 mL/min at screening.
• The subject has cirrhosis (Child-Pugh A, B, or C) or any of the following laboratory values at screening: serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times the upper limit of normal (ULN) or bilirubin >2 × ULN except if the subject has known or suspected Gilbert's disease.
• The subject has a QT interval corrected for heart rate by Fridericia's method (QTcF) value >450 msec if male or >470 msec if female at screening.
• The subject provides a positive response on Question 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) based on the last 6 months or, in the opinion of the investigator, presents a serious risk of suicide at screening.
• The subject had a positive severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) test (any type) result within the 30 days before signing informed consent for Part B (Double-Blind Treatment) or has 2 or more current symptoms (e.g., sore throat, cough, fever) at the same time that are consistent with the Coronavirus disease 2019 (COVID-19) infection (not tested) in the opinion of the investigator.
• The subject has a clinical history that is consistent with a previous COVID-19 infection and has not recovered fully, maintaining nonspecific symptoms like, for example, fatigue, shortness of breath, difficulty concentrating, sleep disorders, fever, anxiety, and depression.
• The subject has previously received BIA 28-6156 or has a known allergy or hypersensitivity to BIA 28-6156 or any components of the formulation.
• The subject is an unsuitable candidate to receive BIA 28-6156 or is unable or unlikely to comply with the dosing schedule or study evaluations in the judgment of the investigator.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BIA 28-6156 10 mg	BIA 28-6156 10 mg	Participants will be randomized to receive BIA 28-6156 10 mg during the Treatment Period.
Placebo	Placebo	Placebo
BIA 28-6156 60 mg	BIA 28-6156 60 mg	Participants will be randomized to receive BIA 28-6156 60 mg during the Treatment Period.

Primary Outcome Measures

Name	Time	Method
Time from baseline to clinically meaningful progression on motor aspects of experiences of daily living (assessed by MDS-UPDRS Part II score and MDS-UPDRS Part III score)	From Baseline up to Week 78	Time from baseline to clinically meaningful progression on motor aspects of experiences of daily living, as assessed by ≥2-point increase from baseline in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score and no improvement in the Motor Examination, as assessed by ≥0-point increase from baseline in MDS-UPDRS Part III score. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be rated by the patient and/or caregiver. Part III assesses the motor signs of PD and is rated by the investigator (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. A higher score indicates more severe symptoms of PD.

Secondary Outcome Measures

Name	Time	Method
Time from baseline to clinically meaningful progression on motor signs of the disease (assessed by MDS-UPDRS Part III score)	From Baseline up to Week 78	Time from baseline to clinically meaningful progression on motor signs of the disease, as assessed by a ≥5-point increase from baseline in the MDS-UPDRS Part III score. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part III assesses the motor signs of PD and is rated by the investigator (Range 0-132). Part III contains 33 scores based on 18 items. A higher score indicates more severe symptoms of PD.
Change from Baseline to Week 78 in the 39-Item Parkinson's Disease Questionnaire (PDQ-39) score	From Baseline up to Week 78	The PDQ-39 is the most thoroughly validated and extensively used self-report measure for the assessment of health-related quality of life in patients with PD. The questionnaire measures 39 items, which assess 8 domains of health: mobility (10 items), activities of daily living (6 items), emotional well being (6 items), stigma (4 items), social support (3 items), cognitions (4 items), communication (3 items), and bodily discomfort (3 items). Each item is scored on the following scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, and 4 = always. Items in each subscale and the total scale can be summarized into an index and transformed linearly to a scale from 0 (perfect health as assessed by the measure) to 100 (worst health as assessed by the measure).
Change from Baseline to Week 78 in the Modified Hoehn and Yahr score	From Baseline up to Week 78	The Modified Hoehn and Yahr scale measures the severity of Parkinson's disease by assessing the patient's motor symptoms and functional impairment. The scale has seven stages, ranging from 1 to 5, with higher scores indicating more severe disease. (1 - Unilateral involvement only; 1.5 - Unilateral and axial involvement; 2 - Bilateral involvement without impairment of balance; 2.5 - Mild bilateral disease with recovery on pull test; 3 - Mild to moderate bilateral disease; some postural instability; physically independent; 4 - Severe disability; still able to walk or stand unassisted; 5 - Wheelchair bound or bedridden unless added).
Time from baseline to any worsening on the Patient Global Impression - Change (PGI-C) scale	From Baseline up to Week 78	The Patient Global Impression of Change (PGI-C) is a self-report tool used to assess a patient's perception of their overall improvement or worsening in a particular health-related domain over time. The PGI-C scale asks patients to rate their overall improvement or worsening since the start of treatment on a seven-point scale, with lower scores indicating greater improvement (1 - Very much improved, 2 - Much improved, 3 - Minimally improved, 4 - No change, 5 - Minimally worse, 6 - Much worse, 7 - Very much worse)
Change from Baseline to Week 78 in the MDS-UPDRS Total (Part I-IV) score	From Baseline up to Week 78	The MDS-UPDRS assesses nonmotor and motor experiences of daily living, motor examination, and motor complication categories. The MDS-UPDRS Part I-IV total score was calculated as the sum of the individual item scores from these categories. Each item is rated on a scale from 0 to 4 on which 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. A higher score indicates more severe symptoms of PD.
Time from baseline to any worsening on the Clinical Global Impression - Change (CGI-C) scale	From Baseline up to Week 78	The Clinical Global Impression of Change (CGI-C) is a scale used to assess the overall clinical improvement or worsening of a patient's condition over time. The CGI-C scale ranges from 1 to 7, with lower scores indicating greater improvement (1 - Very much improved, 2 - Much improved, 3 - Minimally improved, 4 - No change, 5 - Minimally worse, 6 - Much worse, 7 - Very much worse).

Trial Locations

Locations (95)

Cedars-Sinai; 🇺🇸 Los Angeles, California, United States

University of Maryland Medical Center; 🇺🇸 Baltimore, Maryland, United States

Parkinson's Disease and Movement Disorders Cente at University of Pennyslvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Beth Israel Deaconess Medical Center; 🇺🇸 Boston, Massachusetts, United States

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States

The Johns Hopkins University School of Medicine; 🇺🇸 Baltimore, Maryland, United States

CHU de Rennes Hopital Pontchaillou; 🇫🇷 Rennes, France

Parkinson's Center and Movement Disorders of Boca Raton; 🇺🇸 Boca Raton, Florida, United States

Renstar Medical Research; 🇺🇸 Ocala, Florida, United States

Intermountain Healthcare; 🇺🇸 Salt Lake City, Utah, United States

University of Texas Health Science Center - San Antonio; 🇺🇸 San Antonio, Texas, United States

Morehouse School of Medicine; 🇺🇸 Atlanta, Georgia, United States

St. Antonius Ziekenhuis (St. Antonius Hospital) - Utrecht; 🇳🇱 Utrecht, Netherlands

Centrum Medyczne NEUROMED Sp. z o.o. ul.; 🇵🇱 Bydgoszcz, Poland

University of Kentucky; 🇺🇸 Lexington, Kentucky, United States

Baylor College of Medicine; 🇺🇸 Houston, Texas, United States

NeuroKlinika Gabinet Lekarski; 🇵🇱 Łódź, Poland

Centro Hospitalar Universitario de Coimbra; 🇵🇹 Coimbra, Portugal

University of California San Diego; 🇺🇸 La Jolla, California, United States

Amsterdam Medical Center UMC; 🇳🇱 Amsterdam, Netherlands

University Medical Center Groningen; 🇳🇱 Groningen, Netherlands

Centro Hospitalar Universitario de Santo Antonio; 🇵🇹 Porto, Portugal

Hospital Senhora da Oliveira de Guimaraes; 🇵🇹 Guimarães, Portugal

CNS - Campus Neurologico; 🇵🇹 Torres Vedras, Portugal

Struthers Parkinson's Center- East; 🇺🇸 Saint Paul, Minnesota, United States

Krakowkska Akademia Neurologii Sp. z o.o; 🇵🇱 Kraków, Poland

University Hospitals Cleveland Medical Center; 🇺🇸 South Euclid, Ohio, United States

Hospital Vall D´Hebron; 🇪🇸 Barcelona, Spain

University of Miami, Dept. of Neurology; 🇺🇸 Miami, Florida, United States

Rush University Medical Center; 🇺🇸 Chicago, Illinois, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

University of Iowa Hospitals and Clinics; 🇺🇸 Iowa City, Iowa, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

Baylor University Medical Center; 🇺🇸 Baltimore, Maryland, United States

Quest Research Institute, LLC; 🇺🇸 Farmington Hills, Michigan, United States

Icahn School of Medicine at Mount Sinai Beth Israel; 🇺🇸 New York, New York, United States

Park Nicollet Struther's Parkinson's Center (Struthers Parkinsons Center at HealthPartners); 🇺🇸 Saint Paul, Minnesota, United States

Robert Wood Johnson Medical School; 🇺🇸 New Brunswick, New Jersey, United States

Northwell Health Physician Partners; 🇺🇸 New York, New York, United States

Weil Cornell Medical Center; 🇺🇸 New York, New York, United States

Columbia University Medical Center; 🇺🇸 New York, New York, United States

University of Rochester Neurology; 🇺🇸 Rochester, New York, United States

Northwell Health; 🇺🇸 New York, New York, United States

Univerity of Toledo; 🇺🇸 Toledo, Ohio, United States

Vanderbilt Medical Center; 🇺🇸 Nashville, Tennessee, United States

Evergreen Neuroscience Institute; 🇺🇸 Kirkland, Washington, United States

University of Washington; 🇺🇸 Seattle, Washington, United States

Inland Northwest Research; 🇺🇸 Spokane, Washington, United States

Clinique Neuro-Outaouais (Neuro-Outaouais Clinic); 🇨🇦 Gatineau, Quebec, Canada

CHU de Nantes - Hopital Nord Laennec; 🇫🇷 Nantes, France

Montreal Neurological Institute & Hospital; 🇨🇦 Montréal, Quebec, Canada

CHU de Nimes; 🇫🇷 Nîmes, France

Ottawa Hospital Research Institute; 🇨🇦 Ottawa, Canada

CHU de Nice Hopital Pasteur; 🇫🇷 Nice, France

CIC Toulouse; 🇫🇷 Toulouse, France

Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Pitie-Salpetriere - Centres d'Investigation Clinique (CIC) Paris-Est; 🇫🇷 Paris, France

Neurologisches Fachkrankenhaus für, Bewegungsstörungen und Parkinson; 🇩🇪 Beelitz-Heilstätten, Germany

Hopital Paule de Viguier; 🇫🇷 Toulouse, France

Gertrudis Clinic Biskirchen, Parkinson-Center; 🇩🇪 Biskirchen, Germany

Paracelsus-Elena-Klinik; 🇩🇪 Kassel, Germany

Klinikum der Universität München, Campus Grosshadern, Neurologische Klinik und Poliklinik; 🇩🇪 Munich, Germany

Universitats klinikum Marburg; 🇩🇪 Marburg, Germany

Ludwig-Maximilians University Munich; 🇩🇪 Munich, Germany

IRCCS Istituto Delle Scienze Neurologiche DI; 🇮🇹 Bologna, Italy

Parkinson-Klinik Ortenau GmbH&Co KG; 🇩🇪 Wolfach, Germany

Spedali Civilia di Brescia; 🇮🇹 Brescia, Italy

Ospedale Antonio Perrino; 🇮🇹 Brindisi, Italy

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico; 🇮🇹 Milano, Italy

IRCCS Carlo Besta Neurological Institute; 🇮🇹 Milano, Italy

Universita degli Studi della Campania Luigi Vanvitelli - Clinica Neurologia I; 🇮🇹 Napoli, Italy

IRCSS San Raffaele Pisana; 🇮🇹 Roma, Italy

Universita degli Studi di Padova - Azienda Ospedaliera di Padova - Clinica Neurologica; 🇮🇹 Padova, Italy

A.O.U. San Giovanni di Dio Ruggi d'Aragona Centro Parkinson- Piano Rialzato Corpo QT; 🇮🇹 Salerno, Italy

Istituto Clinico Humanitas; 🇮🇹 Rozzano, Italy

Hospital S.JOÃO; 🇵🇹 Porto, Portugal

Hospital Universitario Cruces; 🇪🇸 Barakaldo, Spain

Hospital Universitari Germans Trias i Pujol; 🇪🇸 Badalona, Spain

Hospital de la Santa Creu I Sant Pau; 🇪🇸 Barcelona, Spain

Hospital Universitaio de La Princesa; 🇪🇸 Madrid, Spain

Hospital Ruber Internacional; 🇪🇸 Madrid, Spain

Hospital Universitario Virgen del Rocio; 🇪🇸 Sevilla, Spain

Skane University Hospital, Lund University; 🇸🇪 Lund, Sweden

Neurologmottagningen, QD 62; 🇸🇪 Uppsala, Sweden

NHS Tayside-Ninewells Hospital and Medical School; 🇬🇧 Dundee, United Kingdom

Glasgow Memory Clinic; 🇬🇧 Glasgow, United Kingdom

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital; 🇬🇧 Newcastle Upon Tyne, United Kingdom

King's College London - David Goldberg Centre; 🇬🇧 London, United Kingdom

University Hospitals Plymouth NHS Trust; 🇬🇧 Plymouth, United Kingdom

University of Colorado; 🇺🇸 Aurora, Colorado, United States

Barrow Neurological Institute; 🇺🇸 Phoenix, Arizona, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States

MUSC; 🇺🇸 Charleston, South Carolina, United States

Thomas Jefferson University; 🇺🇸 Philadelphia, Pennsylvania, United States

University of Kansas Medical Center; 🇺🇸 Kansas City, Kansas, United States